Abstract 5144: Epigenetic reprogramming by tumor-derived EZH2 gain of function mutants leads to aggressive 3D-cell morphologies in both epithelial and melanoma cells
Robert A. Rollins(Pfizer (United States)), Dominique Verhelle(Pfizer (United States)), Stephen G. Dann(Pfizer (United States)), Michael Ryskin(Pfizer (United States)), Anthony M. Barsotti(Deerfield (United States)), Wenyan Zhong(Huazhong Agricultural University), Timothy C. Nichols(University of North Carolina at Chapel Hill), Kim Arndt(Pfizer (United States)), Andreas Giannakou(Pfizer (United States)), Conglin Fan(Pfizer (United States)), Christine Loreth(Pfizer (United States)), Gary Li(National Eczema Association), Paul A. Rejto(Pfizer (United States)), Michelle Lee(Pfizer (United States)), Weiguo Zhang(Universidade Estadual de Londrina), Maximillian T. Follettie(Pfizer (United States)), Veronica Diesl(Pfizer (United States)), Jonathon Golas(Pfizer (United States))
Cited by 0
Related Papers
Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer
|Nature Genetics|2014|1.1k
Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer
|Nature Genetics|2011|775
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
|British Journal of Cancer|2020|357